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ABSTRACT 
 
 Macrophages are a heterogeneous population of cells and, include classically 
activated macrophages (M1) and alternatively activated macrophages (M2). Macrophages 
can change from M1 to M2 and vice versa in response to environmental stimuli. Serum 
Amyloid P (SAP) is a constitutive plasma protein that polarizes macrophages to an M2 
phenotype, and part of this effect is mediated through FcRI receptors. In an effort to find 
ways to alter macrophage phenotypes, we screened for compounds that can block the SAP- 
FcRI interaction. From a screen of 3000 compounds, we found 12 compounds that 
reduced the ability of fluorescently labeled human SAP to bind cells expressing human 
FcRI. Based on cell surface marker expression, 8 of the compounds inhibited the effect 
of SAP on skewing human macrophages to an M2 phenotype and in the presence of SAP 
polarized macrophages to an M1 phenotype. In diseases such as tuberculosis, M1 
macrophages are more effective at killing bacteria than M2 macrophages. SAP potentiated 
the numbers of the mycobacterial strains M. smegmatis and M. tuberculosis in 
macrophages. When added along with SAP, 2 of the compounds reduced intracellular 
mycobacterium numbers. Together, these results indicate that blocking SAP effects on 
macrophages can skew these cells toward a M1 phenotype, and this may be useful in 
treating diseases such as tuberculosis. 
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NOMENCLATURE 
 
FCS                             Fetal calf serum 
GFP                            Green fluorescent protein 
GMCSF                      Granulocyte macrophage colony stimulating factor 
HEK293                     Human embryonic kidney cells 293 
ICAM-1                     Intercellular adhesion molecule 1 
IFN-γ                         Interferon-γ   
IL4                            Interleukin 4 
MOI                          Multiplicity of infection 
NCI                           National Cancer Institute 
NOX2                       Nicotinamide adenine dinucleotide phosphate-oxidase 2 
PBMC                      Peripheral blood mononuclear cell 
PBS                          Phosphate buffered saline 
SAP                          Serum amyloid P 
NF-κB                       Nuclear factor kappa-light-chain-enhancer of activated B cells 
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CHAPTER I 
INTRODUCTION 
 
1.1 The development of tuberculosis 
 
Tuberculosis is an airborne disease, which is only surpassed by AIDS in global 
mortality rates [1]. Although tuberculosis is decreasing in parts of the world, in Africa, it 
is still responsible for over 2 million deaths each year. Billions of people infected with 
latent mycobacterium can serve as reservoirs for new active infections [2]. The most 
effective treatment for tuberculosis continues to be antibiotics. However, antibiotic 
treatment is leading to the development of drug-resistant bacteria which are becoming 
more prevalent. The unresolved multidrug-resistant tuberculosis has become one the 
biggest global challenges that people face today [3]. Tuberculosis starts with a 
Mycobacterium tuberculosis infection in the lungs, which then triggers a strong 
inflammatory response and leads to the recruitment of  immune cells, including 
neutrophils [4]. In the lungs, alveolar macrophages are among the first host cells to 
encounter mycobacteria upon infection, and thus the predominant cell-type infected by 
the bacteria [5]. Once infected, mycobacteria are sequestered inside alveolar 
macrophages and become inaccessible to clearing by effector T cells during the early 
stages of infection. Even with an external transfer of T cells prior to infection, the 
protective effect will not start until several weeks after the initial infection [6] . Upon 
infection, the lung tissue undergoes extensive remodeling to generate a macrophage-
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enriched granuloma, a structure where immune cells and bacteria colocalize. For 
unknown reasons, some granulomas control bacteria whereas others permit bacteria 
dissemination [7]. 
 
The adaptive immune response can show up as late as 8 weeks after infection, 
which indicates that the innate immune systems responsible for controlling the early 
stages of the infection [8]. This delay in the adaptive immune response is due to the 
prolonged stay of mycobacteria in mononuclear phagocytes. After infecting a 
macrophage for 10 days, the mycobacteria start to grow significantly and spread to other 
myeloid cells[9]. Alveolar macrophages appear to provide a favorable niche for 
mycobacteria to grow. The reasoning has been largely attributed to the inability of the 
lysosome to fuse with the mycobacteria phagosome [10]. Alveolar macrophages are 
critical in eliminating mycobacteria at early stages of tuberculosis infection and are also 
needed to provoke an adaptive immune response[11]. 
 
1.2 Macrophage polarization and mycobacteria infection 
 
Macrophage polarization is a key component controlling the microenvironment 
of macrophages. Several cytokines that drive macrophage polarization have been 
identified. Cytokine signals translate into a status change for the macrophages, which in 
turn, modulates its cellular function and affects their antimicrobial capabilities. During 
the infection, the interactions between the mycobacteria and the macrophages are 
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constantly changing the microenvironment, and thus it is difficult to generalize the 
pattern as disease progresses. Studies have shown that pushing M1 macrophage 
polarization can improve the general outcome of M.tuberculosis infection [12]. 
Mycobacteria interfere with M1 polarization by secreting virulence factors. Early 
secreted antigenic target protein-6 (ESAT-6) directly inhibits the activation of NF-κB 
and IFN- regulatory factors downstream of Toll-like receptor 2 (TLR2) [13]. The 
inhibited responses to IFN by mycobacteria also includes FcR1[14]. Infected 
macrophages also fail to express type 1 helper T cells (Th1) promoting cytokine 
Interleukin 12 (IL12) [15]. However, M1 responsive components INF- and IL12 are 
generally essential in protecting from TB infection [16, 17]. 
 
Some patients also showed a profound increase in M2 macrophage gene 
expression after tuberculosis infection [18]. The reduction of pro-inflammatory signals 
together with the increase of anti-inflammatory signals leads to unrestrained 
mycobacteria replication. Although it is widely accepted that a protective immune 
response to tuberculosis infection depends on the host’s ability to initiate an M1 cellular 
response, it is not clear how well cells respond to extracellular priming signals during 
infection, and how to maintain stable cell phenotypes after stimulation. 
 
Macrophages have remarkable heterogeneity. Marked changes in physiology and 
gene expression can occur when macrophages come into contact with invading 
microorganisms and damaged tissues. There is a complex interplay between 
 4 
 
microenvironmental signals and differentiation signaling that determines macrophage 
identity. During infection, blood monocytes are recruited to the tissues and differentiate 
into macrophages. The cells acquire a distinct functional phenotype depending on the 
microenvironment. 
 
The progression of tuberculosis is closely related to the macrophage profile in 
tuberculosis-containing granulomas. Studies have shown that a mycobacteria infection 
will be alleviated with activated macrophages. Mycobacteria can manipulate 
macrophage phenotype or preferentially infect M2 macrophage as a strategy to survive 
[19]. It is reasonable to assume that a group of M1 dominant macrophages will 
outperform a group of M2 dominant macrophages when facing mycobacteria. There is 
evidence that the presence of M2 macrophages is part of the reason for the unresolved 
mycobacterial infections and high levels of M2 macrophage-derived IL-10 are found in 
early ulcerative lesions of Buruli disease [20]. Thus, a potential way to promote 
microbicidal activity would be to induce M1 macrophage cytokine profiles where there 
are decreased levels of IL10 and increased levels of IFN- γ. Also, it has been shown that 
FcR plays a key part in macrophages responding to mycobacteria infection. Uptake of 
IgG-opsonized mycobacteria mediated by FcγR will induce the generation of reactive 
oxygen intermediates (ROI), which promotes the formation of phagolysosomes [13]. 
C57BL/6 mice lacking the γ-chain shared by activating FcγR had increased 
susceptibility and exacerbated immunopathology upon M. tuberculosis challenge, which 
is associated with the production of the immunosuppressive cytokine IL-10 [21]. 
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1.3 Mechanism of IFN- γ on boosting microbicidal activity 
 
Mycobacteria block the acidification of the vacuole, which inactivates the 
majority of lysosome hydrolases. Blocking phagosome maturation depends on the 
activation status of host macrophages. Activating cells with cytokines such as IFN- γ can 
reverse this blockage, bringing vacuole pH down from 6.4 to 5.2[22, 23]. Another 
predominant mechanism responsible for restricting M. tuberculosis growth inside the 
cell is through inducible nitric oxide synthase [24]. Oxygen radicals play a significant 
role in killing M. tuberculosis [25]. The level of reactive oxygen intermediates (ROI) 
will increase when stimulated by IFN- γ or LPS [26]. NOS2-/- mice are as susceptible to 
M. tuberculosis infection as are IFN-/- mice [24, 27, 28]. Increased expression level of 
Nitric oxide synthases (NOS) and production of Nitric oxide (NO ) has also been shown 
in M. tuberculosis infected lungs in human patients, indicating the relevance of NO in 
controlling disease progression[29, 30]. 
 
Unlike more common bacterial infections, mycobacteria express the surface lipid 
phthiocerol dimycoceroserate (PDIM) which masks the PAMPs. Therefore, they are not 
“seen” by the host innate immune system and the macrophages are not primed to be 
microbicidal. Another surface lipid, phenolic glycolipid (PGL), is used to induce the 
macrophage chemokine CCL2 to recruit and infect macrophages that are growth-
permissive [31]. These suggest that mycobacteria employ various strategies to avoid 
infecting M1 macrophages. 
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CHAPTER II 
SAP- FCγ RECEPTOR INTERACTION AND ITS EFFECT ON MYCOBACTERIUM 
INFECTION* 
 
2.1 Introduction 
 
Macrophages are a group of heterogeneous cells. Two well-established polarized 
phenotypes are referred to as classically activated macrophage M1, and alternatively 
activated macrophage M2[32]. The classification is largely aligned with Th1 and Th2 
immune responses, however, M1 and M2 cells are not stably differentiated as Th1 and 
Th2 cells[33]. Earlier studies performed in our lab have found that when differentiated 
macrophages are treated with SAP, they will change their expression profile and 
phenotype, acquiring M2 macrophage features[34]. The effect of SAP on macrophage 
polarization was identified through the different expression levels of macrophage 
markers: IRF5, ICAM-1(M1) and IRF4, CD206(M2)[35]. Since SAP pushes 
macrophages to become M2 macrophages, it is important to find out if the skewed 
macrophages could fight mycobacteria efficiently when infected. 
 
 
                                                 
* Parts of this chapter is reprinted with permission from “Identification of compounds that decrease 
numbers of Mycobacteria in human macrophages in the presence of serum amyloid P” by Wang 
Xiang, 2017. Journal of Leukocyte Biology, Volume 102, 857-869, Copyright [2017] by Wiley Online 
Library. 
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2.2 Materials and methods 
 
Macrophage polarization  
Human blood was collected from adult volunteers who gave written consent and 
with specific approval from the Texas A&M University human subjects Institutional 
Review Board.  The only criterion for donor selection was that they described 
themselves as being healthy. Blood collection and isolation of PBMCs was done as 
described previously[36]. The PBMCs were resuspended to 1 x 106 cells/ml in RPMI-
1640 (Lonza, Allendale, NJ), and 250 µl were placed in each well of a type 89626 µ-
Plate 96 well plate (Ibidi, Madison, WI). After 2 hours at 37 ˚C in a humidified 5% CO2 
incubator, gentle pipetting was used to remove non-adherent cells [37, 38]. The medium 
was replaced with 250 µl of serum medium (10% FCS (Seradigm, VWR, Radnor, PA), 
100 U/ml Penicillin/Streptomycin (Lonza), and 2 mM glutamine (Lonza) in RPMI). At 
day 7, the medium was replaced with serum-free medium (10 mM HEPES (Lonza), 2 
mM glutamine, 100 U/ml penicillin/streptomycin, and 1 x ITS-3 (Sigma-Aldrich, St. 
Louis, MO), 1mM sodium pyruvate (Lonza), and 1 x non-essential amino acids (Lonza) 
in RPMI). Human SAP (Calbiochem, San Diego, CA) was buffer exchanged to 20 mM 
sodium phosphate pH 7.4 using a 0.5 ml 10 kDa cutoff Amicon Ultra centrifugal 
concentrator (Sigma). Compounds (stored in 100% DMSO), were diluted in RPMI to 
100 µM. Where indicated, SAP and/or compounds were added at day 7 to the cells to 5 
µg/ml and 1µM final concentration, respectively. After an additional 3 days (day 10 after 
isolating the PBMC), cells were air-dried, fixed, and stained by immunocytochemistry 
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for CD54 or CD206 as previously described [39]. Approximately 100 to 200 
macrophages were examined, and the number of macrophages and the number of the 
macrophages that showed staining was recorded. All experiments used PBMCs from at 
least 3 different blood donors, and 2 technical replicates for each donor. The average of 
the two technical replicates was then calculated, and the results are expressed as the 
mean ± SEM of the three or more averages, with each average from a different donor. 
We never used the same donor twice for a given experiment. 
 
 
Bacterial cultures 
 M. smegmatis Mc2-155 [40] (a gift from Jim Sacchettini, BioBio, TAMU) was 
grown at 37˚C on 7H10 (Becton Dickinson, Franklin Lakes, NJ) plates supplemented 
with 0.2% glucose and 0.083% NaCl, or in shaking culture in 3 ml 7H9 (Becton 
Dickinson) medium supplemented with 0.2% glucose, 0.083% NaCl, and 0.07% Tween 
80 (Sigma) [41]. M-cherry-labeled M. tuberculosis Mc2-7000 transformed with a 
mCherry hygroR plasmid [42, 43] (a gift from Jim Sacchettini) were grown as 
previously described [44]. 
 
Mtb infection assay, M. smegmatis infection assay 
 PBMCs were isolated, plated, and non-adherent cells were removed as described 
above. The enriched monocytes in each well were cultured in 200 µl of serum medium 
supplemented with 10 ng/ml GMCSF (Biolegend, San Diego, CA) for 7 days. The 
medium was then changed to serum-free medium with or without 5 µg/ml SAP and/or 1 
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µM compound. 3 days later (day 10 after isolating PBMC), cells from an overnight M. 
smegmatis culture at an OD 600 of ~1 were vortexed with ColiRoller Plating beads 
(Thermo Fisher) at high for 10 minutes with an analog vortex mixer (VWR, Radnor, 
PA). After allowing the beads to settle out, the supernatant was decanted and sonicated 
at power 6 for 30 seconds 6 times using a Sonic Dismembrator 60 (Fisher, Waltham, 
MA). Clumped bacteria were removed by centrifugation at 50 x g for 6 minutes at room 
temperature. The OD 600 of the supernatant containing non-clumped bacteria was 
measured to estimate the bacterial concentration, with an OD600 of 1 equivalent to 3.13 
× 107 cfu/ml [45]. Before infection, cells in one well were washed with PBS, treated 
with Trypsin-versene Mixture (Lonza) at 37 ˚C for 5 minutes to detach cells, and cells 
were counted. M. smegmatis was diluted in RPMI/ 10% FCS/ 2 mM glutamine (and no 
antibiotics), and incubated with macrophages for 4 hours using a MOI of 10 with respect 
to the cell count described above. After incubation, cells were gently washed with 37 ˚C 
PBS 3 times, and cultured with RPMI/ 10% FCS/ 2 mM glutamine/ 20ug/ml gentamicin 
(Thermo Fisher Scientific) to kill bacteria outside the cells [46, 47]. At 48 hours after the 
infection, the cells were lysed with ice-cold 0.5% Tween 20 in water. Serial dilutions of 
the cell lysates were plated on 7H10 plates supplemented as described above, and 
colonies were counted after 3 days at 37 ˚C. 
 
 M-cherry expressing M. tuberculosis infection was done as described above with 
the exception that the M. tuberculosis was incubated with macrophages for 4 hours in 
RPMI/ 10% FCS/ 25 µg/ml pantothenic acid (Sigma). After infection, the macrophages 
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were washed as above and cultured in RPMI/ 10% FCS/ 20 µg/ml gentamicin/ 25 µg/ml 
pantothenic acid. After 4 days, cells were imaged using an IN Cell Analyzer 2000 (GE, 
Fairfield, CT) in 6 randomly selected fields of view from each well with a 20 x objective 
in the Texas Red channel and a 0.05 second exposure. Phase images were also taken. 
Pairs of images were analyzed using IN Cell Developer Toolbox 1.8 (GE), with the 
segmentation and sieve parameters adjusted to count macrophages detected in the phase 
images with internalized fluorescent bacteria. Phagocytosis of bacteria was measured as 
the amounts of bacteria inside macrophages at 2 hours after the cells were changed back 
into gentamicin medium.   
 
 
2.3 Results 
 
SAP polarized macrophages become Mtb-tolerant 
 M2 macrophages appear to be more associated with tuberculosis than M1 
macrophages [48-52]. In agreement with this, we observed that compared to unpolarized 
human macrophages, human macrophages polarized to a M1 phenotype with interferon–
 (IFN-) [53] showed decreased numbers of intracellular M. smegmatis at 48 hours after 
infection, and a decreased percentage of cells infected with M. tuberculosis at 5 days 
after infection (Figure 1A). In addition to M1 and Mreg, macrophages can also be 
polarized to a pro-fibrotic M2a phenotype with interleukin 4 (IL-4) [54, 55], and we 
observed that compared to unpolarized macrophages, polarization of macrophages to a 
M2a phenotype with IL4 resulted in increased numbers of intracellular M. smegmatis 
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and an increased percentage of cells infected with M. tuberculosis (Figure 1A). The 
survival of mycobacteria within macrophages over infection was measured by 
comparing the 0 hour time point after infection to 48 hours (M. smegmatis) or 5 days (M. 
tuberculosis) after infection. In the absence of added factors, the number of M. 
smegmatis cells decreased, while the number of M. tuberculosis cells increased (Figure 
11).  
 
 
 
 
Figure 1. Changes in the numbers of intracellular M. smegmatis and M.tuberculosis 
during infection. PBMCs were cultured as in Figure 6. A) M. smegmatis counts are 
shown as colony numbers per macrophage. B) M. tuberculosis numbers were measured 
as total fluorescence intensity per well. Values are mean ± SEM, n=3 different donors. 
*** indicates p < 0.001 (t test). 
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 Mycobacterium infection appears to potentiate M2 macrophages [56]. SAP also 
potentiates M2 macrophages and inhibits M1 macrophages [34, 57]. To test the 
prediction that SAP potentiates Mycobacterium infection of macrophages, we added 
Mycobacterium bacteria to macrophages in the presence or absence of SAP. SAP 
potentiated the number of intracellular M. smegmatis at 48 hours after infection, and 
potentiated the percentage of macrophages infected with M. tuberculosis at 5 days after 
infection (Figure 1B).  
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Figure 2. SAP potentiates the number of intracellular mycobacteria. A) Human 
PBMCs were cultured in 10% FCS/ RPMI with 10 µg/ml GMCSF for 8 days and, 
treated with IFN-γ or IL4 for an additional 2 days. Cells were then infected with M. 
smegmatis or recombinant M. tuberculosis expressing a fluorescent protein. M. 
smegmatis infected cells were lysed and bacteria were plated at 48 hours post infection, 
and colonies were counted. M. tuberculosis fluorescence was imaged at 5 days post 
infection. B) PBMCs were similarly cultured with GMCSF for 7 days, and then cultured 
for an additional 3 days in the presence or absence of SAP. Mycobacteria were measured 
as in panel A. Values are mean ± SEM, n=3 different donors. * indicates p < 0.05 (t test).  
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2.4 Discussion 
 
SAP is a constitutive component of plasma [58], and SAP also appears to be 
present in the extracellular space of tissues [59]. We and others found that SAP regulates 
monocyte and macrophage phenotypes at least in part through its binding to FcRI [60, 
61].  
 
Under conditions such as SAP with 27H8, the number of cells expressing CD54 
increased and the number of cells expressing CD206 also increased, suggesting that 
some cells may have been expressing both markers. Under other conditions, the percent 
of CD54+ cells and the percent of CD206+ cells did not add up to 100, indicating that 
some cells may not have expressed either marker. As has been observed by others [62, 
63], both results suggest that in the presence of some of the compounds, some 
macrophages develop a phenotype that is not perfectly M1 or perfectly M2.  
 
 
 
 
 
 
 
 
 15 
 
 
CHAPTER III 
SCREENING FOR COMPOUND INHIBITORS OF SAP-FC RECEPTOR 
INTERACTION* 
 
3.1 Introduction 
 
When performing preliminary experiments, we were able to show which receptor 
was involved in this polarizing effect of SAP. Human monocytes express FcγRI, 
FcγRIIa, FcγRIIb, and FcγRIIIa [64].  All corresponding orthologs in mice are: FcγRI, 
FcγRII, FcγRIIb, FcγRIIIa. All Fcγ receptors showed different levels of binding affinity 
to SAP, among which FcγRI has the highest binding affinity[60]. Both Fc receptor 
knockout mice and siRNA knockdowns of human receptor were used to demonstrate the 
necessity of certain Fcγ receptors. The results suggest that SAP binds to FcγRI on 
monocytes to inhibit fibrocyte differentiation[60]. We show that SAP is partially acting 
through FcγRI when polarizing macrophages. Thus, if the interaction between SAP and 
cell surface receptor FcγRI is interrupted by a chemical compound, it can slow or stop 
disease progression by manipulating and skewing the macrophage phenotype. As a 
component of human blood and a marker in tuberculosis[65], SAP is related to 
                                                 
* Parts of this chapter is reprinted with permission from “Identification of compounds that decrease 
numbers of Mycobacteria in human macrophages in the presence of serum amyloid P” by Wang 
Xiang, 2017. Journal of Leukocyte Biology, Volume 102, 857-869, Copyright [2017] by Wiley Online 
Library. 
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tuberculosis infection progression, and it is critical to come up with a strategy to block 
the effect. 
 
3.2 Materials and methods 
 
SAP binding to FcγRI 
 The binding of SAP labeled with Dylight 650 NHS Ester (Thermo Fisher 
Scientific, Waltham, MA) to HEK293 cells transfected with plasmids driving expression 
of FcγRI-GFP and Fcε common γ-chain was done following [60] with the exception that 
cells were transfected using a 4D-Nucleofector (Lonza, Allendale, NJ) with the preset 
parameters for HEK293 cells. The SAP binding was measured as median fluorescence 
intensity. The fluorescence intensity from SAP binding was normalized as 100 and all 
compounds group were compared to SAP. Libraries containing 10 mM or 1 mM of 
compounds were obtained from the National Cancer Institute (Diversity and Mechanistic 
Diversity Sets). To reduce assay size, compounds were initially pooled (Kainkaryam and 
Woolf 2009) into groups of 10 compounds immediately before doing the assays (Elkin, 
Harden et al. 2015). The NCI compound collections are sent out in 96 well plates, with 
10 compounds per row. Pools 1A to 9H corresponded to rows from compound plates 
4762/62-4776/29 from the Diversity set IV library, pools 17A to 23H corresponded to 
compound plates 4784/29-4790/18 from the Diversity set IV library, and pools 24A to 
32H corresponded to compound plates 4791/18-4800/18 from the Mechanistic Diversity 
set II library. 1 µl of drug pool containing 100 µM of each drug in 100% DMSO (VWR, 
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Radnor, PA) was mixed with 50 µl of binding buffer containing labeled SAP, and this 
was then mixed with 50 µl of cells. For follow-up of active pools, the 12 compounds that 
inhibited SAP binding were ordered as specific compounds from the NCI repository, and 
these were used for subsequent studies, including the rescreening of these compounds 
for their ability to inhibit SAP binding. None of the 12 compounds have been used in 
clinical trials.  
 
3.3 Results 
 
Identification of compounds that decrease SAP binding to FcγR1 
 To identify compounds that can block SAP binding to FcγR1, we used Fluor647 to 
label SAP, and transfected HEK293 cells with GFP-tagged FcγR1. The binding of labeled 
SAP to the FcγR1 expressed on HEK293 cells was measured by flow cytometry. Using 
this method, we previously observed a KD of 4.6 nM for SAP binding to FcγR1 [60]. Due 
to transfection efficiency, only some cells expressed FcγR1. Since the FcγR1 was tagged 
with GFP, we were able to identify FcγR1+ and FcγR1- cells by flow cytometry. The 
binding of SAP to the FcγR1- cells was used to measure nonspecific binding, which was 
subtracted from the SAP binding to FcγR1+ cells to obtain SAP binding to FcγR1. Pools 
of 10 compounds, containing 1 µM final concentration of compound in the assay, were 
assayed for their ability to reduce the binding of 80 nM SAP (10 µg/ml) to FcγR1. From 
a screen of 200 pools, 9 pools decreased SAP binding and 11 pools increased SAP binding 
(Figure 1).  
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            We retested the 9 compound pools that significantly reduced the binding of SAP 
to FcγR1, and additionally retested 15 pools that appeared to decrease SAP binding 
although without achieving statistical significance (Figure 2). 6 of the pools again showed 
an inhibition of SAP binding. The 60 individual compounds from these 6 pools were then 
assayed for inhibition of SAP binding at a final compound concentration of 1 µM, and 12 
compounds decreased SAP binding (Figure 3). When re-tested at a variety of compound 
concentrations, all 12 compounds significantly decreased SAP binding (Figure 4). The 
structures of the compounds are shown in Table 1. 
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Figure 3. Identification of compound pools which decrease SAP binding to HEK293 
cells expressing FcγR1. HEK293 cells expressing FcγR1 were incubated with 10 µg/ml 
fluorescently-labeled SAP and the indicated compound pools. Flow cytometry was then 
used to measure SAP binding to the cells. The binding was measured as median 
fluorescence intensity. The binding of the labeled SAP to FcγR1 negative cells was used 
to estimate non-specific binding, and this was subtracted from total binding. Values are 
mean ± SEM, n=3 independent experiments. * indicates p < 0.05, ** p < 0.01 (1-way 
ANOVA, Fisher’s test compared to SAP and no compound).  
 
 
 20 
 
 
 
Figure 4. Second round of screening. Compound pools that significantly decreased 
SAP binding, along with pools that potentially decreased binding, were re-screened as in 
Figure 1. Values are mean ± SEM, n=3 independent experiments. * indicates p < 0.05 
(1-way ANOVA, Dunnett’s test compared to SAP and no compound). 
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Figure 5. Screening of individual compounds for ability to decrease SAP binding. 
Individual compounds from the pools that significantly decreased SAP binding in Figure 
2 were screened as in Figure 1. Values are mean ± SEM, n=3 independent experiments. 
* indicates p < 0.05, ** p < 0.01 (1-way ANOVA, Dunnett’s test compared to SAP and 
no compound). 
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Figure 6. The reduction of SAP binding as a function of compound concentration. 
Compounds that significantly decreased SAP binding in Figure 3 were tested at the 
indicated concentrations for their ability to decrease the binding of fluorescently-labeled 
SAP to HEK293 cells expressing FcγR1 as in Figure 1. Values are mean ± SEM, n=3 
independent experiments. * indicates p <0.05, ** p < 0.01, *** p < 0.001 (1-way 
ANOVA, Dunnett’s test compared to SAP and no compound). Lines are nonlinear 
regression fits to a one-site competitive binding curve, using a SAP concentration of 80 
nM, and 4.6 nM for the KD of SAP binding to FcγR1. 
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Table 1. Compounds and their effects on macrophage phenotype and mycobacteria 
infection. This table lists the compounds that decreased SAP binding. Arrows pointing 
up indicate that the compound significantly increased marker expression (Figure 5) 
compared to the SAP only group; arrows pointing down indicate that the compound 
significantly decreased marker expression or mycobacterial growth (Figure 7) compared 
to SAP only group. Structures were obtained from the NCI compounds library database. 
The structure of 28F6 is incorrect in this database, the 28F6 structure shown here is from 
PubChem. 
 
 
Code 
NSC 
number 
Structure CD54  
 
CD206  
 
M. 
smegmatis 
infection 
M. 
tuberculosis 
infection 
4D7 88882 
 
    
19E3 7419 
 
    
19E8 91356 
 
    
21G2 5856 
 
    
21G3 57608 
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Table 1 Continued  
 
21G8 15910 
 
    
27H2 622690 
 
    
27H8 643162 
 
    
28F2 327697      
28F5 77021 
 
    
28F6 262665 
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Table 1 Continued  
 
29C2 2186 
 
    
 
 
 
3.4 Discussion 
 
We screened a small compound library and found 12 compounds that inhibit 
human SAP binding to cells expressing human FcRI. Eight of the compounds blocked 
the ability of human SAP to increase the expression of an M2 marker or decrease the 
expression of an M1 marker.  The 12 compounds identified in the initial screen were 
only able to inhibit SAP binding to cells expressing FcRI by ~20%, indicating that the 
identified compounds are far from optimal binding inhibitors. 
 
 How the compounds inhibit SAP binding is unknown, as they could directly 
interfere at the SAP-FcRI binding site, allosterically alter the extracellular conformation 
of either of the two proteins, or act inside cells to allosterically alter the conformation of 
FcRI. If a compound binds to FcRI in such a way that it interferes with the ability of 
FcRI to bind the Fc domain of an antibody that is pathogen-bound a pathogen, that 
compound could possibly have the undesired side effect of decreasing the ability of cells 
to uptake antibody-bound pathogens. Although 27H2, 27H8, and 28F2 all have 
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dimethylamines on an aromatic ring, 27H8 and 28F6 have   unsaturated carbonyl 
groups, and 19E3, 27H2, 27H8, 28F2, 28F5, and 28F6 all have electrophilic centers. 
There does not appear to be any consistent structural feature in the 12 compounds, nor 
do the compounds that have a specific effect on a marker or numbers of mycobacterium 
in macrophages have a structural consistency(Table 1). This diversity supports the idea 
that the compounds could affect macrophages at a variety of binding sites. 
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CHAPTER IV 
INVESTIGATE THE EFFECT OF COMPOUND INHIBITOR ON MACROPHAGE 
PHENOTYPE AND MYCOBACTERIA INFECTION* 
 
4.1 Introduction 
 
Since the M1 and M2 macrophage ratio is the key to resolving mycobacteria 
infection at early stage[12], and compound inhibitors can block SAP binding to FcγRI to 
some extent. It is important to investigate the ability of the lead compound to alleviate 
the outcome of a mycobacteria infection. To confirm whether the compounds skewed the 
macrophage phenotype specifically through FcγRI, the infection result will be compared 
in presence or absence of SAP.  
 
4.2 Materials and methods 
 
Macrophage viability  
 Macrophage viability assays were done as described for the infection assay, 
except that at 48 hours after M. smegmatis infection or 4 days after M. tuberculosis 
infection, macrophages were washed with Hanks’ buffer (Sigma), and then incubated for 
                                                 
* Parts of this chapter is reprinted with permission from “Identification of compounds that decrease 
numbers of Mycobacteria in human macrophages in the presence of serum amyloid P” by Wang 
Xiang, 2017. Journal of Leukocyte Biology, Volume 102, 857-869, Copyright [2017] by Wiley Online 
Library. 
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15 minutes at 37°C with 165 nM Sytox green (Life Technologies, Carlsbad, CA) in 
Hanks’ buffer. The medium was then removed and replaced with Hanks’ buffer, and 
cells were imaged with a 20 x objective on an IN Cell 2000 in the FITC channel with an 
exposure time of 0.05 seconds. 
 
M. smegmatis viability  
 M. smegmatis were grown in liquid culture to an OD 600 of ~1 and were then 
diluted in 7H9 medium supplemented as described above to an OD 600 of 0.005. In a 
well of 80040LE 0910 clear flat-bottom 96 well plate (Thermo Fisher), 196 µl of diluted 
bacteria were mixed with 4 µl of compound (diluted in DMSO) and incubated at 37 ˚C. 
After 24 hours, 20 µl of Deep Blue cell viability compound (resasurin; Biolegend) was 
added to each well, and incubated at 37 ˚C for 2 hours. Fluorescence was measured on a 
Synergy Mx plate reader (Biotek, Winooski, VT) following the manufacturer’s 
directions. 
 
Statistics 
 Statistical analysis with t tests or 1-way ANOVA with appropriate post test, and 
curve fits, were done using GraphPad Prism 4 (GraphPad, San Diego, CA). Fisher’s 
Least Significant Difference test was used for the ANOVA post test during the initial 
screening stage to improve the sensitivity of the screening. Subsequently, the hit 
compounds were tested again to rule out potential false positives, and comparisons were 
done using Dunnett’s post test. Significance was defined as p < 0.05.  
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4.3 Results 
 
Some compounds that decrease SAP binding to FcγR1 decrease SAP effects on 
macrophages 
 SAP potentiates the polarization of macrophages to an anti-inflammatory Mreg 
(M2c) phenotype [34, 66]. To determine if the compounds that reduce SAP binding to 
FcγR1 can reduce the ability of SAP to potentiate M2c macrophages, we examined the 
effects of the compounds in the presence or absence of SAP on macrophage phenotype. 
Human PBMCs were cultured for 6 days to allow the monocytes to differentiate into 
macrophages, and the cells were then washed and cultured in the presence or absence of 
SAP and compounds for 3 days. The cells were then fixed and stained, and the percent 
of the macrophages that stained for a given marker was measured. Representative 
images for the control group are shown in Figure 12. ICAM-1 (CD54) is a 
proinflammatory M1 macrophage marker [67-69]. In the absence of SAP, 4D7, 21G2, 
27H2 and 28F6 significantly decreased the percent of macrophages showing ICAM-1 
staining (Figure 5A). SAP also decreased the percent of ICAM-1+ macrophages, and 
compared to SAP alone, 19E3, 19E8, 27H2, 27H8 and 28F2 in the presence of SAP 
significantly increased the percent of ICAM-1+ macrophages (Figure 5A). CD206 is an 
Mreg (M2c) macrophage marker [70]. In the absence of SAP, 4D7, 21G3, 28F5 and 
28F6 significantly increased the percent of macrophages that were CD206+ (Figure 5B). 
SAP also increased the percent of CD206+ macrophages, and compared to SAP alone, 
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27H2, 28F2, 28F5, 28F6 and 29C2 in the presence of SAP significantly decreased 
CD206+ macrophages (Figure 5B). 
 
 
 
 
Figure 7. Immunocytochemistry staining of the macrophage markers CD54 and 
CD206. PBMC were cultured as in Figure 5. A) Cells were fixed and stained for the M1 
marker ICAM-1 (CD54) or B) the M2 marker CD206. Cells were then counterstained 
with hematoxylin. Positive staining was identified by red staining, with nuclei 
counterstained blue. Photos show representative results from 3 different donors. Bar is 
50 µm. 
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Figure 8. Some compounds which decrease SAP binding affect macrophage marker 
expression. Human PBMCs were cultured for 6 days to allow macrophage 
differentiation, and were then cultured for an additional 3 days in the presence or 
absence of SAP and the indicated compounds. A) Cells were fixed and stained for the 
M1 marker ICAM-1 (CD54) or B) the M2 marker CD206. The number of 
morphologically identifiable macrophages that stained for the indicated marker were 
then counted and expressed as a percentage of macrophages. Values are mean ± SEM, 
n=3 different donors. # indicates p < 0.05 (t test compared to control). * indicates p<0.05 
(1-way ANOVA, Dunnett’s test comparing compounds in the absence of SAP to the 
control, and compounds incubated with SAP to SAP alone). 
 32 
 
Some SAP- FcγR1 inhibitors decrease mycobacteria numbers in infected macrophages  
 Since some of the compounds that decrease SAP binding to FcγR1 also inhibit 
the effect of SAP on macrophages, we determined whether any of these compounds 
might affect the number of Mycobacterium in macrophages. Human PBMCs were 
cultured for 6 days to allow the monocytes to differentiate into macrophages, and the 
cells were then washed and cultured in the presence or absence of SAP and compounds 
for 3 days. The medium was then removed and medium containing Mycobacterium was 
then added. After 4 hours, the macrophages were washed to remove non-internalized 
bacteria and cultured for 2 or 4 days. The level of internal Mycobacterium was then 
measured. In the absence of SAP, 27H2 increased the number of intracellular M. 
smegmatis at 48 hours after infection (Figure 7A). SAP also increased the number of 
intracellular M. smegmatis, and compared to SAP alone, in the presence of SAP, 19E3, 
27H2, 27H8, 28F2, 28F5 and 28F6 decreased the number of intracellular M. smegmatis 
(Figure 7A). In the absence of SAP, 21G8 and 28F5 increased the percentage of 
macrophages infected with M. tuberculosis at 4 days after infection (Figure 7B), and 
compared to SAP alone, in the presence of SAP 27H8, 28F2, 28F6 and 29C2 decreased 
whereas 21G8 increased the percentage of macrophages infected with M. tuberculosis 
(Figure 7B). 
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Figure 9. Some compounds inhibit the number of intracellular mycobacteria in the 
presence of SAP. PBMCs were cultured as in Figure 6B, with the exception that the 
indicated compounds were added in the presence or absence of SAP for the 3 days 
before bacterial infection. A) M. smegmatis were measured as in Figure 6. B) The 
percent of macrophages infected with M. tuberculosis was measured as in Figure 6. 
Values are mean ± SEM, n=3 different donors. # indicates p < 0.05 (t test compared to 
control). * indicates p < 0.05 (1-way ANOVA, Dunnett’s test).  
 
 
 
Confirmation of lead compounds’ activity on macrophage infection  
 We found that in the presence of SAP, 7 compounds inhibited either M. 
smegmatis or M. tuberculosis numbers inside macrophages. To determine if these 
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compounds are directly inhibiting Mycobacterium growth and/or proliferation, we added 
these compounds to M. smegmatis for 24 hours. We then quantified the amounts of live 
bacteria with the fluorescent dye resazurin. Compound 27H2 killed bacteria at 
concentrations of 4 µM and above, similar to the killing ability of the antibiotic 
rifampicin (Figure 8). However, in the mycobacteria infection assay, compound 27H2 
did not kill bacteria directly because the concentration used was 1 µM, and the 
compounds were washed off before adding in bacteria. The other 6 compounds did not 
significantly affect M. smegmatis viability (Figure 8). These results indicate that 6 of the 
compounds we identified improve the response of SAP-exposed macrophages to 
mycobacteria infection.  
 
 
 
 
Figure 10. The direct effect of compounds on M. smegmatis proliferation and 
growth. M. smegmatis was grown for 24 hours in the presence of the indicated 
concentrations of compounds, and then incubated with resazurin for 2 hours. Growth 
was measured as the fluorescence intensity of reduced resazurin. Values are mean ± 
SEM, n=3 independent experiments. * indicates p < 0.05 (t test compared to DMSO 
control).  
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Another possible reason that the compounds might appear to decrease the 
numbers of bacteria inside macrophages is that the compounds decrease macrophage 
viability. To test this possibility, we did compound treatments and Mycobacterium 
infections as described for Figure 7, and measured macrophage viability using Sytox 
green to stain for dead macrophages. In the M. smegmatis model, we observed that 
approximately 10% of the macrophages were dead at 48 hours after adding bacteria to 
macrophages, and that SAP did not significantly affect this percentage (Figure 9A-F). Of 
the 6 compounds that, in the presence of SAP, decreased the number of intracellular M. 
smegmatis in macrophages, only 5 µM 28F6 increased the percentage of dead 
macrophages (Figure 9F). At 4 days after M. tuberculosis infection, SAP did not 
significantly increase the number of dead macrophages (Figure 9G). Of the 4 compounds 
that, in the presence of SAP, decreased the percentage of macrophages infected with M. 
tuberculosis at 4 days after infection, 29C2 increased the percentage of dead 
macrophages in the absence of SAP, but in the presence of SAP, none of the 4 
compounds had a significant effect on macrophage viability (Figure 9G). Together, these 
results suggest that 5 µM 28F6 decreases macrophage viability in the presence of SAP, 
while the other compounds appear to potentiate the response of macrophages to 
Mycobacterium infection in the presence of SAP rather than inhibiting macrophage 
viability. 
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Figure 11. The effect of compounds on macrophage viability. Macrophages were 
cultured and infected as in Figure 6. A-F) Macrophage viability was measured by 
staining with Sytox Green at 48 hours after M. smegmatis infection, and the percent of 
dead cells in images was calculated.  * in F indicates p < 0.05 for 5 µg/ml SAP (t test 
compared to control). G) Macrophage viability was measured at 5 days after M. 
tuberculosis infection as in panels A-F. Values in A-G are mean ± SEM, n=3 different 
donors. * indicates p < 0.05 compared to DMSO control (1-way ANOVA, Dunnett’s 
test).  
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SAP and the compounds could potentially alter the ability of macrophages to 
bind to and/or internalize bacteria. To determine if SAP and/or the identified compounds 
affect these processes, we infected macrophages with bacteria as described for Figure 7, 
and then lysed macrophages immediately after washing off bacteria that had not been 
internalized. Neither SAP nor the 6 compounds that decreased M. smegmatis affected the 
phagocytosis of M. smegmatis (Figure 10A), and neither SAP nor the compounds that 
decreased M. tuberculosis affected the phagocytosis of M. tuberculosis (Figure 10B).  
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Figure 12. The effect of compounds on phagocytosis of bacteria by macrophages. 
Macrophages were cultured and infected as in Figure 6. After infection, macrophages 
were treated with gentamycin for 2 hours to remove extracellular bacteria. A) M. 
smegmatis infected cells were then lysed immediately after the 2-hour gentamycin 
treatment, bacteria were plated, and colonies were counted. B) M. tuberculosis 
fluorescence was imaged immediately after the 2-hour gentamycin treatment. Values are 
mean ±SEM, n = 3 different donors. No values were significantly different from the 
DMSO controls (1-way ANOVA, Dunnett’s test).  
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4.4 Discussion 
 
As predicted, pre-exposure of human macrophages to human SAP potentiated the 
number of mycobacteria in the macrophages. Some but not all of the compounds 
reduced the effect of SAP. Compounds 27H8, 28F2 and 28F6 effectively ameliorate 
both M. tuberculosis and M. smegmatis infection, although 28F6 may have a moderate 
cytotoxic effect at high concentration. Together, these results indicate that blocking the 
human SAP – human FcRI interaction could be a potential method to decrease the 
ability of mycobacteria to proliferate in human macrophages. This contrasts with the 
effect of mouse SAP on mouse alveolar macrophages, where mouse SAP decreases the 
uptake and number of M. tuberculosis bacteria in mouse alveolar macrophages [71]. 
This difference may be due either to differences between mice and humans, or as a result 
of a different response between circulating monocyte-derived macrophages and alveolar 
macrophages. 
 
 Some compounds that inhibited SAP binding had no significant effect on the 
ability of SAP to decrease expression of the M1 marker CD54 and increase expression 
of the M2 marker CD206, suggesting that they may have partially activated FcRI while 
inhibiting SAP binding. Several of the compounds mimicked the effect of SAP on CD54 
and/or CD206 expression (Figure 5), indicating that they may interact directly with 
FcRI. Compound 27H2 decreased expression of the M1 marker CD54 in the absence of 
SAP, but increased CD 54 expression in the presence of SAP, while compounds 28F5 
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and 28F6 increased expression of the M2 marker CD 206 in the absence of SAP, but 
decreased CD206 expression in the presence of SAP. This indicates that these 
compounds can act as SAP agonists or SAP antagonists depending on whether SAP is 
present. 
 
 In the presence or absence of SAP, compounds 27H8 and 28F2 did not affect the 
initial uptake of mycobacteria by macrophages, the viability of mycobacteria in the 
absence of macrophages, or the viability of macrophages. However, in the presence of 
SAP, these two compounds reduced the number of M. smegmatis bacteria in 
macrophages by two days after infection and reduced the percentage of macrophages 
containing M. tuberculosis by five days after infection. Together, this indicates that in 
the presence of SAP, 27H8 and 28F2 may have induced some macrophages to kill their 
ingested bacteria. By comparing figures 10B and 7B, indications are that over the four 
days of M. tuberculosis infection, there is an increase in the percentage of infected 
macrophages. An alternative possibility is that in the presence of SAP, 27H8 and 28F2 
may have inhibited the spread of M. tuberculosis from one macrophage to another. In 
addition to helping macrophages kill the internalized mycobacteria, altering the 
macrophage phenotype may be useful for the treatment of diseases such as cancer and 
obesity [72, 73]. Together with our results, this suggests that blocking SAP effects on 
macrophages may be useful for a variety of diseases. However, SAP also appears to 
prevent the development of fibrosis [74], so use of this approach would need to proceed 
with some caution.  
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CHAPTER V 
SUMMARY 
 
Macrophages are a group of heterogeneous cells. When macrophage cell-typess 
are imbalanced, it can indicate different diseases. During the progression of tuberculosis 
infection, M2 macrophages are predominant. Protein serum amyloid P is also involved 
in the development of the disease and used as a diagnostic marker. We reasoned that 
SAP promoted mycobacteria growth by converting macrophages from one type to the 
other. Macrophage plasticity allow them to respond to environmental signal changes 
accordingly. Therefore, the project focused on employing the versatility of macrophages 
to affect the outcome of mycobacteria infection. Earlier research has shown that 
macrophages experience a phenotype conversion in presence of Serum amyloid P. The 
work started by searching for compound inhibitors of SAP-Fc receptor. These potential 
lead compounds were tested on their ability to reverse macrophage phenotypes and 
create a functional conversion. 
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